WARNING LETTER

February 26, 2007

Tom Young
CEO
Qualitest Pharmaceuticals, Inc .
130 Vintage Drive NE
Huntsville, Alabama 35811-8216

Dear Mr. Young:

This letter is written in reference to the marketing by your firm of Bellaspas Tablets, a drug product containing ergotamine tartrate.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing product that you market is identical,related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the “new drug” determination made under this DESI proceeding applies to your product and therefore your product requires an approved new drug application before it may be lawfully sold. As there is no approved new drug application on file with the FDA for Bellaspas Tablets as marketed by your firm,the marketing of this product is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Bellaspas Tablets is a prescription drug within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. § 201.5 .Consequently, Bellaspas Tablets’ labeling fails to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(fl(1)]. Because it lacks an approved application, it is not exempt from this requirement under 21 C.F.R. § 201.115. Bellaspas Tablets is therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Bellaspas Tablets with CYP 3A4 inhibitors also renders the product misbranded under section 502(fl(2) of the Act, [21 U.S.C. § 352(f)(2)], because its labeling fails to bear adequate warning.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Bellaspas Tablets as currently formulated, manufactured, and labeled, is effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including Bellaspas Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of Bellaspas Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in its entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”),)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301)827-8904.

For information regarding the drug approval process see www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

Douglas Ginter
President
Nucare Pharmaceuticals Inc.
622 West Katella Avenue
Orange, California 92867

Dear Mr. Ginter:

This letter is written in reference to the marketing by your firm of Bellamine S Tablets, a drug product containing ergotamine tartrate.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing product that you market is identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the”new drug” determination made under this DESI proceeding applies to your product and therefore your product requires an approved new drug application before it maybe lawfully sold. As there is no approved new drug application on file with the FDA for Bellamine S Tablets as marketed by your firm, the marketing of this product is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Bellamine S Tablets is a prescription drug within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. §201.5. Consequently, Bellamine S Tablets’ labeling fails to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(f)(1)]. Because it lacks an approved application, it is not exempt from this requirement under 21 C.F.R. § 201.115. Bellamine S Tablets is therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Bellamine S Tablets with CYP 3A4 inhibitors also renders the product misbranded under section 502(fl(2) of the Act, [21 U.S.C. § 352(f)(2)], because its labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Bellamine S Tablets as currently formulated, manufactured, and labeled, is effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs -Compliance Policy Guide”(”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine- containing products made by such firms, including Bellamine S Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of Bellamine S Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in its entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see
www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

Richard Reeves
President
Murfreesboro Pharmaceutical Nursing Supply
1843 Memorial Blvd
Murfreesboro, Tennessee 37129
Dear Mr. Reeves:

This letter is written in reference to the marketing by your firm of drug products containing ergotamine tartrate, specifically, Bellamine S Tablets and Eperbel S Tablets.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing products that you market are identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the “new drug” determination made under this DESI proceeding applies to your products and therefore your products require an approved new drug application before they may be lawfully sold. As there are no approved new drug applications on file with the FDA for any of the drug products, Bellamine S Tablets and Eperbel S Tablets as marketed by your firm, the marketing of these products is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Bellamine S Tablets and Eperbel S Tablets are prescription drugs within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because they are not safe for use except under the supervision of a practitioner licensed by law to administer such drugs. By definition, prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for a its intended uses. See 21 C.F.R. § 201.5. Consequently, Bellamine S Tablets and Eperbel S Tablets’ labeling fail to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. §352(f)(1)]. Because each lacks an approved application, each is not exempt from this requirement under 21 C.F.R. § 201.115. Bellamine S Tablets and Eperbel S Tablets are therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug product sand determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Bellamine S Tablets and Eperbel S Tablets with CYP 3A4 inhibitors also renders these products misbranded under section 502(fl(2) of the Act, [21 U.S.C.,. § 352(f)(2)], because each product’s labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Bellamine S Tablets and Eperbel S Tablets as currently formulated, manufactured, and labeled, are effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs -Compliance Policy Guide”(”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including Bellamine S Tablets and Eperbel S Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of each drug, Bellamine S Tablets and Eperbel S Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in their entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301)827-8904.

For information regarding the drug approval process see
www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

President and/or CEO
Lini Inc.
665 East Lincoln Avenue
Rahway, New Jersey 07065

Dear Mr. or Ms. President and/or CEO:

This letter is written in reference to the marketing by your firm of drug products containing ergotamine tartrate, specifically, Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program . On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing products that you market are identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310 .6(b)(2), the”new drug” determination made under this DESI proceeding applies to your products and therefore your products require an approved new drug application before they may be lawfully sold. As there are no approved new drug applications on file with the FDA for any of the drug products, Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets as marketed by your firm, the marketing of these products is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets are prescription drugs within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because they are not safe for use except under the supervision of a practitioner licensed by law to administer such drugs. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. §201.5. Consequently, Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets’ labeling fail to bear adequate directions for use under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. Because each lacks an approved application, each is not exempt from this requirement under 21 C.F.R. § 201.115. Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets are therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use.

Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets with CYP 3A4 inhibitors also renders these products misbranded under section 502(f)(2) of the Act, [21 U.S.C. § 352(f)(2)], because each product’s labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets as currently formulated, manufactured, and labeled, are effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of each drug, Bell Phen Ergot S Tablets, Bellaspas Tablets, and Bellamine Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in their entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F.3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see
http://www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency unapproved drugs coordinator at t (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

George C. Halvorson
CEO
Kaiser Foundation Hosptials
300-A Pullman Street
Livermore, California 94551

Dear Mr. Halvorson:

This letter is written in reference to the marketing by your firm of Belladonna Alka/Ergotamine and PB (Bellamine S) tablets, a drug product containing ergotamine tartrate.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of’ the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg.15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing product that you market is identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the “new drug” determination made under this DESI proceeding applies to your product and therefore your product requires an approved new drug application before it may be lawfully sold. As there is no approved new drug application on file with the FDA for Belladonna Alka/Ergotamine and PB (Bellamine S) tablets as marketed by your firm, the marketing of this product is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Belladonna A1kalErgotamine and PB (Bellamine S) tablets is a prescription drug within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. § 201.5. Consequently, Belladonna Alka/Ergotamine and PB (Bellamine S) tablets’ labeling fails to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(f)(1)]. Because it lacks an approved application, it is not exempt from this requirement under 21 C.F.R. § 201.115. Belladonna Alka/Ergotamine and PB (Bellamine S) tablets is therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Belladonna Alka/Ergotamine and PB (Bellamine S) tablets with CYP 3A4 inhibitors also renders the product misbranded under section 502(f)(2) of the Act, [21 U.S.C. § 352(f)(2)], because its labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modem standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Belladonna Alka/Ergotamine and PB (Bellamine S) tablets as currently formulated, manufactured, and labeled, is effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. www.fda.gov/cder/guidance/6911fnl.pdf .The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including Belladonna Alka/Ergotamine and PB (Bellamine S) tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• The agency intends to take enforcement action against unapproved ergotamine-containing products and those who cause them to be manufactured or shipped in interstate commerce (whether or not they have received a warning letter from FDA) after these dates.
• a statement of the amount of Belladonna Alka/Ergotamine and PB (Bellamine S) tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in its entirety, and your plan for disposition of any inventory remaining after the above shipment
  cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see
www.fda.gov/cder/regulatory/applications/default.htm.Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

Michael J. Burns, Ph.d
Rafick Henein, Ph.D.
President and CEO
IVAX Pharmaceuticals Inc. (formerly Goldline Laboratories Inc.)
4400 Biscayne Boulevard
Miami, Florida 33137

Dear Dr. Henein:

This letter is written in reference to the marketing by your firm of Bel-Phen-Ergot S Tablets, a drug product containing ergotamine tartrate.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing product that you market is identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the”new drug” determination made under this DESI proceeding applies to your product and therefore your product requires an approved new drug application before it maybe lawfully sold. As there is no approved new drug application on file with the FDA for Bel-Phen-Ergot S Tablets as marketed by your firm, the marketing of this product is in violation of sections 301(d) and 505(a) of the Act, [21U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Bel-Phen-Ergot S Tablets is a prescription drug within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. §201.5. Consequently, Bel-Phen-Ergot S Tablets’ labeling fails to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(f)(1)]. Because it lacks an approved application, it is not exempt from this requirement under 21 C.F.R. § 201.115. Bel-Phen-Ergot S Tablets is therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug product sand determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Bel-Phen-Ergot S Tablets with CYP 3A4 inhibitors also renders the product misbranded under section 502(f)(2) of the Act, [21 U.S.C. § 352(f)(2)], because its labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Bel-Phen- Ergot S Tablets as currently formulated, manufactured, and labeled, is effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your finn is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs-Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such finns, including Bel-Phen-Ergot S Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a finn is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your finn of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of Bel-Phen-Ergot S Tablets, and any other unapproved
• ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in its entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see http://www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

Michael J. Burns, Ph.D.
President
Ferndale Laboratories Inc .
780 West 8 Mile Road
Ferndale, Michigan 48220

Dear Dr. Burns:

This letter is written in reference to the marketing by your firm of drug products containing ergotamine tartrate, specifically, phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing products that you market are identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the”new drug” determination made under this DESI proceeding applies to your products and therefore your products require an approved new drug application before they may be lawfully sold. As there are no approved new drug applications on file with the FDA for any of the drug products, phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets as marketed by your firm, the marketing of these products is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets are prescription drugs within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because they are not safe for use except under the supervision of a practitioner licensed by law to administer such drugs. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. § 201.5. Consequently, phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets’ labeling fail to bear adequate directions for use under section 502(fl(1) of the Act, [21 U.S.C. § 352(f)(1)]. Because each lacks an approved application, each is not exempt from this requirement under 21 C.F.R. § 201.115. phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets are therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets with CYP 3A4 inhibitors also renders these products misbranded under section 502(fl(2) of the Act, [21 U.S.C. § 352(f)(2)], because each product’s labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modem standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets as currently formulated, manufactured, and labeled, are effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations . If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of each drug, phenobarbital, ergotamine, and belladonna tablets, Bellamine Tablets, and Spastrin Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control ;
• the time period in which you expect such inventory to be exhausted, in their entirety,and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see. For information regarding the drug approval process see www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.
Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

President and/or CEO
Excellium Pharmaceutical Inc.
3 G Oak Road
Fairfield, New Jersey 07004

Dear Mr. or Ms. President and/or CEO:

This letter is written in reference to the marketing by your firm of Eperbel S Tablets, a drug product containing ergotamine tartrate.

safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program . On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing product that you market is identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the”new drug” determination made under this DESI proceeding applies to your product and therefore your product requires an approved new drug application before it may be lawfully sold. As there is no approved new drug application on file with the FDA for Eperbel S Tablets as marketed by your firm, the marketing of this product is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C. §§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Eperbel S Tablets is a prescription drug within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. § 201.5. Consequently, Eperbel S Tablets’ labeling fails to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(f)1)]. Because it lacks an approved application, it is not exempt from this requirement under 21 C.F.R. § 201.115. Eperbel S Tablets is therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include : protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Eperbel S Tablets with CYP 3A4 inhibitors also renders the product misbranded under section 502(f)(2) of the Act, [21 U.S.C. § 352(f)(2)], because its labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk. in general because they may not meet modem standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that Eperbel S Tablets as currently formulated, manufactured, and labeled, is effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine -containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including Eperbel S Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of Eperbel S Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in its entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F.3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

Edward King
President
DSC Laboratories
1979 Latimer Drive
Muskegon, Michigan 49442

Dear Mr. King:

This letter is written in reference to the marketing by your firm of drug products containing ergotamine tartrate, specifically, caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing products that you market are identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the “new drug” determination made under this DESI proceeding applies to your products and therefore your products requires an approved new drug applications before it may be lawfully sold. As there is no approved new drug application on file with the FDA for any of the drug products, caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories as marketed by your firm, the marketing of these products is in violation of sections 301(d) and 505(a) of the Act.[21 U.S.C. §§ 331(d) and 355(a)), which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories are prescription drugs within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because they are not safe for use except under the supervision of a practitioner licensed by law to administer such drugs. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. § 201.5. Consequently, caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories’ labeling fail to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(f)(1)]. Because each lacks an approved application, each is not exempt from this requirement under 21 C.F.R. § 201.115. caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories are therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include: protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories with CYP 3A4 inhibitors also renders these products misbranded under section 502( fl(2) of the Act, [21 U.S.C. § 352(f)(2)], because each product’s labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessarily mean that caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories as currently formulated, manufactured, and labeled, are effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with a11 requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations . If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine- containing products made by such firms, including caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of each drug, caffeine ergotamine, and pentobarbital suppositories and Bellcomp PB suppositories, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control ;
• the time period in which you expect such inventory to be exhausted, in their entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15} days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 21 D F.3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see
http://www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,
2
Michael Levy,
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research

WARNING LETTER

February 26, 2007

Bernie Talley
DRX Pharmaceutical Consultants Inc.
8315 Monticello Avenue
Skokie, Illinois 60076

Dear Mr. Talley:

This letter is written in reference to the marketing by your firm of Bellamine S Tablets, a drug product containing ergotamine tartrate.

Drug products containing ergotamine that were marketed under new drug applications approved for safety only prior to 1962 were reviewed under the Drug Efficacy Study Implementation (DESI) program. On July 27, 1972, the Agency concluded that such products are new drugs effective for the treatment or prevention of “vascular headaches” (”e.g. migraine, migraine variants or `histaminic cephalalgia”‘) subject to section 505 of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 355] and that approved new drug applications are required to market them. (37 Fed. Reg. 15032).

Under 21 C.F.R. § 310.6(b)(1), the ergotamine-containing product that you market is identical, related, or similar to the drugs reviewed in this DESI proceeding. Under 21 C.F.R. § 310.6(b)(2), the”new drug” determination made under this DESI proceeding applies to your product and therefore your product requires an approved new drug application before it may be lawfully sold. As there is no approved new drug application on file with the FDA for Bellamine S Tablets as marketed by your firm, the marketing of this product is in violation of sections 301(d) and 505(a) of the Act, [21 U.S.C.§§ 331(d) and 355(a)], which prohibit the introduction or delivery for introduction into interstate commerce of a new drug without an approved new drug application.

Moreover, Bellamine S Tablets is a prescription drug within the meaning of section 503(b)(1) of the Act, [21 U.S.C. § 353(b)(1)], because it is not safe for use except under the supervision of a practitioner licensed by law to administer such drug. By definition, a prescription drug’s directions for use are not adequate to enable a layperson to safely use the drug for its intended uses. See 21 C.F.R. § 201.5. Consequently, Bellamine S Tablets’ labeling fails to bear adequate directions for use under section 502(f)(1) of the Act, [21 U.S.C. § 352(f)(1)]. Because it lacks an approved application, it is not exempt from this requirement under 21 C.F.R. § 201.115. Bellamine S Tablets is therefore misbranded.

Further, we note that FDA has reviewed and approved several ergotamine-containing drug products and determined that such products require warning information to be placed in a prominently displayed box pursuant to 21 C.F.R. § 201.57. This boxed warning is required to prevent use of potent CYP 3A4 inhibitors with ergotamine-containing products. Serious and/or life-threatening ischemia, including fatalities and cases of gangrene, has resulted from such concomitant use. Examples of potent CYP 3A4 inhibitors include : protease inhibitors, macrolide antibiotics, and antifungal agents. Your failure to display this warning regarding concomitant use of Bellamine S Tablets with CYP 3A4 inhibitors also renders the product misbranded under section 502( fl(2) of the Act, [21 U.S.C. § 352(f)(2)], because its labeling fails to bear adequate warnings.

In addition to the serious health concern presented by your omission of this important warning, unapproved drugs are a public health risk in general because they may not meet modern standards for safety, effectiveness, quality, and labeling. Even though some ergotamine products were found to be effective for certain indications via the DESI process, this does not necessary mean that Bellamine S Tablets as currently formulated, manufactured, and labeled, is effective or safe.

The above identified violations are not intended to be an all inclusive list of violations involving your facility. It is your responsibility to assure that your firm is in compliance with all requirements of the Act. We request that you review all drug products that you are currently marketing to assure they are in compliance with the Act and FDA regulations. If you no longer market any ergotamine-containing drug products or believe that you have received this letter in error, please notify the Agency at the address below.

As described in the guidance entitled “Marketed Unapproved Drugs - Compliance Policy Guide” (”Marketed Unapproved Drugs CPG”), the Agency may exercise its enforcement discretion and identify a period of time during which the Agency does not intend to initiate an enforcement action against a currently marketed unapproved drug. http://www.fda.gov/cder/guidance/6911fnl.pdf. The Agency intends to exercise its enforcement discretion with regard to unapproved, ergotamine-containing drug products as follows. FDA does not intend to initiate enforcement actions related to currently manufactured unapproved ergotamine-containing products if those products are listed with FDA under section 510 of the Act, [21 U.S.C. § 360], as of the date of this letter, unless the manufacturing of those products continues after April 27, 2007. Further, FDA does not intend to initiate enforcement actions related to the shipment in interstate commerce of unapproved ergotamine-containing products made by such firms, including Bellamine S Tablets, unless they are still being shipped on or after August 25, 2007 1.

You should be aware that the Agency does not intend to exercise its enforcement discretion as described in this letter in the following circumstances: (1) if a firm is violating other provisions of the Act; (2) when it appears that a firm, in response to this letter, increases its manufacture or distribution of unapproved ergotamine drug products above its usual volume during these periods; (3) if FDA learns of new information regarding any serious health risk or hazards associated with an unapproved ergotamine drug product; or (4) if a firm marketing unapproved ergotamine products does not undertake appropriate corrective action to cease marketing the products.

To avail your firm of these periods during which the Agency intends to exercise enforcement discretion regarding unapproved ergotamine products, you must reply within fifteen (15) days of your receipt of this letter with a commitment to comply with the conditions stated above. Please include:

• a statement(s) of what action you plan to take to comply;
• a statement of the amount of Bellamine S Tablets, and any other unapproved ergotamine-containing product, that is (are) in inventory under your control;
• the time period in which you expect such inventory to be exhausted, in its entirety, and your plan for disposition of any inventory remaining after the above shipment cessation date; and
• an estimate of when products in distribution channels will become exhausted.

If FDA receives your commitment within fifteen (15) days of your receipt of this letter, the agency intends to exercise its enforcement discretion as described above, unless the circumstances listed above or lack of compliance with the conditions set forth in this letter warrant further action. If FDA does not receive a commitment within fifteen (15) days of receipt of this letter or a firm or person fails to comply with the stop manufacture or stop shipment date, the agency may take immediate regulatory action, including but not limited to seizure and/or injunction. If FDA takes action, to preserve limited agency resources, FDA may also take simultaneous enforcement action relating to any other unapproved new drugs manufactured, distributed, or shipped by the defendant. (See, e.g., United States v. Sage Pharmaceuticals, 210 F3d 475, 479-480 (5th Cir. 2000) (the agency can combine all violations of the act in one proceeding, rather than taking action against a firm with multiple violations of the act in “piecemeal fashion”).)

In addition, FDA cautions firms against reformulating their products into ergotamine-free unapproved new drugs that are marketed under the same name or substantially the same name (including a new name that contains the old name). In the Marketed Unapproved Drugs CPG, FDA states that it intends to give higher priority to enforcement actions involving unapproved drugs that are reformulated to evade an FDA enforcement action. In addition, reformulated products marketed under a name previously identified with a different active ingredient or combination of active ingredients have the potential to confuse health care practitioners and harm patients.

Please send your reply via fax, as well as mail or overnight delivery to: Valerie L. Whipp, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of New Drugs and Labeling Compliance, 11919 Rockville Pike, HFD-310, Rockville, MD 20852, fax number (301) 827-8904.

For information regarding the drug approval process see
http://www.fda.gov/cder/regulatory/applications/default.htm. Should you wish to seek approval for your ergotamine product, you may contact Sally Loewke, MD, the Agency’s unapproved drugs coordinator at (301) 796-0710, who can help you identify the appropriate review division or office for further direction. However, until such time as you have FDA approval for your product, you must comply with this letter.

Sincerely yours,

/S/

Michael Levy
Director
Division of New Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research